OT mobile menu

Search form


Skin Cancer / Melanoma Targets

Skin Cancer / Melanoma Targets

Avelumab, an investigational fully human monoclonal IgG1 antibody against programmed death-ligand 1 (anti-PD-L1), is receiving orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of Merkel cell carcinoma.

“Liquid biopsy” assays of circulating tumor cells (CTCs) should be conducted using arterial rather than venous blood specimens, according to a small study of 17 patients with metastatic uveal melanoma.

The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for treating patients with BRAF V600 wild-type unresectable or metastatic melanoma.

Patients whose metastatic melanoma responded to pembrolizumab (Keytruda) immunotherapy had higher baseline frequencies of circulating immune T cells positive for CD8, programmed cell death protein 1 (PD-1), and Bim.

A new nationwide clinical trial comparing two groups of drugs for treating melanoma is marking a new era in the treatment of melanoma and how best to use the latest molecular tools.

In the real-world setting, about one-third of melanoma patients treated with ipilimumab had grade 3 or worse immune-related adverse events.

The US Food and Drug Administration (FDA) have granted a priority review for Merck’s anti-PD-1 agent pembrolizumab (Keytruda) as a first-line treatment of advanced melanoma, the company announced.


Subscribe to Skin Cancer / Melanoma Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.